ERBB2 and breast carcinoma: Freedman RA et al.(Freedman et al. 2016) conducted a multicenter, open-label phase 2 trial, the Translational Breast Cancer Research Consortium (TBCRC) 022 trial, where 40 patients with HER2-positive BC who had brain metastasis (≥ 1 cm in the longest dimension) received neratinib 240 mg once daily as monotherapy; these patients had progressed over previous CNS-directed therapy, such as whole brain radiotherapy (WBRT), stereotactic radiosurgery (SRS), surgery, or any combination.